Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Rating of “Moderate Buy” from Analysts

Bright Minds Biosciences Inc. (NASDAQ:DRUG) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $124.50.

A number of research firms have issued reports on DRUG. Zacks Research lowered Bright Minds Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 2nd. HC Wainwright increased their price objective on Bright Minds Biosciences from $115.00 to $145.00 and gave the company a “buy” rating in a research report on Wednesday. Wall Street Zen downgraded shares of Bright Minds Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Robert W. Baird set a $126.00 target price on shares of Bright Minds Biosciences in a research report on Friday, February 13th. Finally, BTIG Research reiterated a “buy” rating and set a $147.00 target price on shares of Bright Minds Biosciences in a research note on Tuesday, February 17th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC lifted its stake in shares of Bright Minds Biosciences by 0.9% in the fourth quarter. Janus Henderson Group PLC now owns 1,155,995 shares of the company’s stock valued at $90,832,000 after buying an additional 10,335 shares during the period. Sio Capital Management LLC increased its position in shares of Bright Minds Biosciences by 0.9% during the second quarter. Sio Capital Management LLC now owns 512,338 shares of the company’s stock valued at $13,377,000 after purchasing an additional 4,776 shares during the period. Vivo Capital LLC raised its stake in shares of Bright Minds Biosciences by 99.4% in the third quarter. Vivo Capital LLC now owns 501,617 shares of the company’s stock valued at $30,428,000 after purchasing an additional 250,045 shares in the last quarter. Braidwell LP raised its stake in shares of Bright Minds Biosciences by 6.8% in the fourth quarter. Braidwell LP now owns 324,358 shares of the company’s stock valued at $25,313,000 after purchasing an additional 20,673 shares in the last quarter. Finally, MPM Bioimpact LLC bought a new position in Bright Minds Biosciences in the fourth quarter worth $17,961,000. Institutional investors own 40.52% of the company’s stock.

Bright Minds Biosciences News Roundup

Here are the key news stories impacting Bright Minds Biosciences this week:

• Positive Sentiment: HC Wainwright retained a “Buy” rating and a $145 price target and raised long‑range upside — notably lifting FY2030 EPS to $3.51 (from $2.24) — which supports a bullish longer‑term view. Read More.
• Positive Sentiment: Some near‑term estimates were improved: HC Wainwright raised FY2026 forecast (less negative: -$6.19 vs -$6.94 prior) and increased Q2 2026 and Q3 2026 estimates, signaling partially better-than-expected operational pacing in the coming quarters. Read More.
• Neutral Sentiment: Reported short‑interest data in the filings shows zero shares short (with anomalous NaN changes), an unclear data point that neither confirms meaningful short pressure nor provides actionable insight. Read More.
• Negative Sentiment: HC Wainwright cut several near‑term and medium‑term forecasts — including FY2027 (to -$9.22 from -$8.75) and FY2029 (to -$3.94) and trimmed multiple 2027 quarterly EPS estimates — indicating larger expected losses before the company reaches profitability and pressuring the stock in the short term. Read More.
• Negative Sentiment: Overall the note is mixed but leans toward deeper near‑term losses despite long‑term upside; investors focused on short‑term cash burn and milestone timing likely sold shares in response. Read More.

Bright Minds Biosciences Price Performance

Bright Minds Biosciences stock opened at $76.87 on Tuesday. The firm has a market cap of $747.95 million, a price-to-earnings ratio of -39.83 and a beta of -6.04. Bright Minds Biosciences has a fifty-two week low of $23.17 and a fifty-two week high of $123.75. The firm has a fifty day moving average price of $82.86 and a two-hundred day moving average price of $68.06.

Bright Minds Biosciences (NASDAQ:DRUG) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.28. As a group, sell-side analysts expect that Bright Minds Biosciences will post -1.24 earnings per share for the current year.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.